National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-DR5 agonist monoclonal antibody TRA-8
An agonist mouse monoclonal antibody directed against TRAIL death receptor type 5 (DR5) with potential antineoplastic activity. Anti-DR5 agonist monoclonal antibody TRA-8 binds DR5, which may induce apoptosis in DR5-expressing tumor cells. DR5 is a tumor cell surface ligand that crosslinks with death receptor type 4 (DR4) when bound by TRAIL [Tumor necrosis (TNF)-related apoptosis-inducing ligand], triggering apoptosis via a death receptor signaling pathway. The apoptotic activity of this antibody may not require DR4/DR5 crosslinking. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-death receptor 5 agonist monoclonal antibody TRA-8
Code name:TRA-8



Previous:anti-CD70 monoclonal antibody MDX-1411, anti-CEA IgCD28TCR-transduced autologous T cells, anti-CEA/anti-DTPA-In (F6-734) bispecific antibody, anti-CS1 monoclonal antibody HuLuc63, anti-denatured collagen recombinant monoclonal antibody TRC093
Next:anti-EGFR monoclonal antibody RO5083945, anti-EGFRvIII vaccine CDX-110, anti-endoglin monoclonal antibody TRC105, anti-EpCAM antibody fragment -Pseudomonas exotoxin fusion protein, anti-EpCAM antibody fragment-bouganin fusion protein

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov